Anlotinib hydrochloride
ApprovedSmall molecule
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Anlotinib hydrochloride is one of 691 small molecule programs targeting Glioma. It is currently in Approved.
30
Indications
82
Total Trials
16
Active Trials
690
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 30 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Anlotinib hydrochloride
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Approved
Nolvadex
SSan Diego Pacific Oncology & Hematology Associates
Preclinical
Gemzar
GGynecologic Oncology Group
Preclinical
Megace
Bristol-Myers SquibbPreclinical
DATROWAY
Daiichi SankyoPreclinical
MS Contin
Merck & Co.Preclinical
Lupron
EEastern Cooperative Oncology Group
Preclinical
Recentin
NNational Cancer Institute (NCI)
Preclinical
Zoladex
Luye Pharma Group Ltd.Preclinical
QS21
MMemorial Sloan Kettering Cancer Center
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Q4 2026
Phase 2Recruiting
Esophageal Squamous Cell Carcinoma
NCT05252078
Phase 3Active, not recruiting
Metastatic Colorectal Cancer
NCT04854668
Phase 3Active, not recruiting
Hepatocellular Carcinoma
NCT04344158
Phase 2Recruiting
Radiation Therapy
NCT06379087
Phase 2Active, not recruiting
Glioblastoma
NCT04959500
Phase 1/2Not yet recruiting
Melanoma
NCT05539118
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer8 trials
Show 5 more trials
Hepatocellular Carcinoma7 trials
A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
Active, not recruiting·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT04344158·648 enrolled
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT04344158·648 enrolledShow 4 more trials
Novel Treatment of Advanced Hepatocellular Carcinoma
Unknown status·TThe First Affiliated Hospital of Zhengzhou University·Phase 3·NCT03950518·300 enrolled
Lung Cancer4 trials
A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer
Unknown status·TThe First Affiliated Hospital of Guangzhou Medical University·Phase 2·NCT04181372·50 enrolled
Anlotinib4 trials
Show 1 more trial
Soft Tissue Sarcoma4 trials
42 more indications
Small Cell Lung Cancer3 trials
Clinical Study of First-line Treatment of Small Cell Lung Cancer (SCLC) With Anlotinib Hydrochloride
Unknown status·—·Phase 4·NCT03890055·30 enrolled
Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung Cancer
Unknown status·—·Phase 2/3·NCT04192682·40 enrolled
Nasopharyngeal Carcinoma3 trials
Maintenance Treatment2 trials
Second-line Treatment2 trials
Differentiated Thyroid Carcinoma2 trials
Colorectal Cancer2 trials
Anlotinib Combined With mXELIRI as Second-line Treatment of Advanced Colorectal Cancer
Unknown status·GGuangzhou University of Traditional Chinese Medicine·Phase 1/2·NCT05035914·94 enrolled
Adenocarcinoma2 trials
Adjuvant Therapy2 trials
Breast Cancer2 trials
Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer
Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT04624711·40 enrolled
Glioblastoma2 trials
Maintenance Therapy2 trials
A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC
Unknown status·TThe First Affiliated Hospital of Guangzhou Medical University·Phase 2·NCT03700359·60 enrolled
Refractory Sarcoma1 trial
Drug Resistance1 trial
Renal Cell Carcinoma1 trial
Tyrosine Kinase Inhibitor1 trial
Chemotherapy1 trial
Chondrosarcoma1 trial
A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade Chondrosarcoma
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT05193188·70 enrolled
Pancreatic Ductal Adenocarcinoma1 trial
Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Recruiting·SShanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.·Phase 3·NCT07165951·566 enrolled
Metastatic Colorectal Cancer1 trial
A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer
Active, not recruiting·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT04854668·748 enrolled
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT04854668·748 enrolledEndometrial Carcinoma1 trial
Endometrial Cancer1 trial
Metastatic Nasopharyngeal Cancer1 trial
Pancreatic Carcinoma1 trial
Ovarian Cancer1 trial
Diffuse Large B-Cell Lymphoma1 trial
Intrahepatic Cholangiocarcinoma1 trial
Treatment of Advanced Intrahepatic Cholangiocarcinoma
Unknown status·TThe First Affiliated Hospital of Zhengzhou University·Phase 3·NCT03940378·152 enrolled
Multiple Myeloma1 trial
Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple Myeloma
Unknown status·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT05549973·32 enrolled
Efficacy and Safety1 trial
Chemoradiotherapy1 trial
Radiation Therapy1 trial
Triple-Negative Breast Cancer1 trial
Chordoma1 trial
Non-squamous NSCLC1 trial
Melanoma1 trial
Preoperative1 trial
Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma （SPARE-01）
Recruiting·—·Phase 2·NCT05167994·30 enrolled
Neoadjuvant Treatment1 trial
Paraganglioma1 trial
Esophageal Carcinoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Anlotinib hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details